A Single-center, Uncontrolled, Open, Phase 1 Study of Recombinant(Expressed by Pichia Pastoris) Human Serum Albumin/Human Granulocyte-Colony Stimulating Factor(I)Fusion Protein For Injection(GW003)to Metastatic Tumors
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2016
Price : $35 *
At a glance
- Drugs Balugrastim (Primary)
- Indications Neutropenia
- Focus Adverse reactions
- Sponsors Jiangsu T-mab BioPharma
- 22 Feb 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 30 Mar 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 30 Mar 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov record.